SutroVax is a recently established biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. SutroVax is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma`s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.
Conjugate vaccines comprise the largest segment of the vaccine industry with annual sales of approximately $8 billion across multiple licensed indications, including pneumococcus, meningitis, and H flu. By far the largest of those indications is the pneumococcus market with annual sales of nearly $6 billion. Despite the ...
SutroVax is a recently established biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. SutroVax is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma`s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.
Conjugate vaccines comprise the largest segment of the vaccine industry with annual sales of approximately $8 billion across multiple licensed indications, including pneumococcus, meningitis, and H flu. By far the largest of those indications is the pneumococcus market with annual sales of nearly $6 billion. Despite the successes to date, there are not only a significant number of additional bacterial strains that have yet to be incorporated into current conjugate vaccines, but also many infectious diseases that have yet to be addressed using this potent modality.
SutroVax was seed funded by Johnson and Johnson Innovation and Sutro Biopharma.
-
Number of Employees:
0-25
-
Annual Revenue:
$0-1 Million